The fourth-quarter 2019 earnings report of Alnylam Pharmaceuticals Inc. was notable for the stock market’s nonplussed response. This was despite Alnylam’s first product – Onpattro (patisiran), the w
The leader in a field others have abandoned, Alnylam Pharmaceuticals Inc. , has been working hard to make the case that its RNA-interference technology is moving beyond buzz-worthy platform status
“The Pink Sheet” regularly covers significant deal-making in the biopharmaceutical industry. Here is a summary of the most noteworthy transactions occurring between Feb. 28 and March 12. Endo/Salix
Financings During the opening quarter of 2014, biopharma companies raised $9.8 billion (up 53% from Q4), with 18% of the deals having a value of $100 million or greater. ( See Exhibit 1. ) Follow-on p